Sandoz targets industry patent void with $322m Henlius deal

PartnershipPositive

AI Analysis

Summary

Sandoz and Henlius announced a collaboration worth $322 million to develop up to 10 biosimilars, capitalizing on upcoming global biosimilar loss-of-exclusivity opportunities.

Outcome Details

Collaboration on up to 10 biosimilars

Importance:7/10

Sentiment:

0.60

biosimilarspartnershipcollaborationpatent expiryM&A

Related Companies

$SDZ.SW

Read the original article

Published by Pharmaceutical Technology on August 17, 2026 10:47 AM

Read Original